MK-6096: antagonist of orexin receptors 1 and 2; structure in first source [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 25128145 |
| CHEMBL ID | 2107822 |
| SCHEMBL ID | 1716633 |
| MeSH ID | M0575644 |
| Synonym |
|---|
| mk 6096 |
| mk6096 |
| mk-6096 |
| [(2r,5r)-5-[(5-fluoropyridin-2-yl)oxymethyl]-2-methylpiperidin-1-yl]-(5-methyl-2-pyrimidin-2-ylphenyl)methanone |
| filorexant |
| gtpl4460 |
| CHEMBL2107822 |
| 1088991-73-4 |
| filorexant [usan:inn] |
| e6btt8va5z , |
| unii-e6btt8va5z |
| methanone, ((2r,5r)-5-(((5-fluoro-2-pyridinyl)oxy)methyl)-2-methyl-1-piperidinyl)(5-methyl-2-(2-pyrimidinyl)phenyl)- |
| ((2r,5r)-5-(((5-fluoropyridin-2-yl)oxy)methyl)-2-methylpiperidin-1-yl)(5-methyl-2-(pyrimidin-2-yl)phenyl)methanone |
| bdbm104692 |
| D10345 |
| us8569311, e-5 |
| filorexant (usan) |
| filorexant [who-dd] |
| filorexant [usan] |
| [(2r,5r)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone |
| filorexant [inn] |
| CS-4437 |
| SCHEMBL1716633 |
| HY-15653 |
| DTXSID50148764 |
| AKOS027323764 |
| NCGC00484077-01 |
| filorexant(mk-6096) |
| methanone, [(2r,5r)-5-[[(5-fluoro-2-pyridinyl)oxy]methyl]-2-methyl-1-piperidinyl][5-methyl-2-(2-pyrimidinyl)phenyl]- |
| DB12158 |
| mk-6096; filorexant |
| mfcd28100674 |
| EX-A2101 |
| [(2~{r},5~{r})-5-[(5-fluoranylpyridin-2-yl)oxymethyl]-2-methyl-piperidin-1-yl]-(5-methyl-2-pyrimidin-2-yl-phenyl)methanone |
| NT5 , |
| Q18355303 |
| AC-35933 |
| AS-82282 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| Orexin receptor type 1 | Homo sapiens (human) | IC50 | 0.0135 | AID1190417; AID1279957 |
| Orexin receptor type 1 | Homo sapiens (human) | Ki | 0.0021 | AID1190415; AID1237020; AID1279994; AID1582239; AID765089 |
| Orexin receptor type 2 | Homo sapiens (human) | IC50 | 0.0140 | AID1190416; AID1280008 |
| Orexin receptor type 2 | Homo sapiens (human) | Ki | 0.0003 | AID1190414; AID1237021; AID1279993; AID1582240; AID765090 |
| Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | Ki | 0.0003 | AID765090 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1280006 | Oral bioavailability in dog | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804 | Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. |
| AID1280005 | Oral bioavailability in rat | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804 | Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. |
| AID765089 | Binding affinity to orexin receptor 1 (unknown origin) | 2013 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17 ISSN: 1464-3405 | Selective orexin receptor antagonists. |
| AID1279994 | Binding affinity to OX1R (unknown origin) | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804 | Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. |
| AID1279956 | Effect on sleep parameter in po dosed rat by EEG analysis | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804 | Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. |
| AID765090 | Binding affinity to orexin receptor 2 (unknown origin) | 2013 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17 ISSN: 1464-3405 | Selective orexin receptor antagonists. |
| AID1190414 | Antagonist activity at human OX2R by radioligand displacement assay | 2015 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3 ISSN: 1464-3405 | Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant. |
| AID1280007 | Effect on sleep parameter in po dosed dog by EEG analysis | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804 | Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. |
| AID1280001 | Clearance in iv dosed rat | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804 | Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. |
| AID1280000 | Receptor occupancy at OX2R in rat brain assessed as drug level in plasma | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804 | Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. |
| AID1190417 | Antagonist activity at human OX1R by FLIPR assay | 2015 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3 ISSN: 1464-3405 | Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant. |
| AID1190415 | Antagonist activity at human OX1R by radioligand displacement assay | 2015 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3 ISSN: 1464-3405 | Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant. |
| AID1237021 | Antagonist activity at orexin-2 receptor (unknown origin) | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 ISSN: 1464-3405 | Recent trends in orexin research--2010 to 2015. |
| AID1280008 | Antagonist activity at human OX2R expressed in CHO cell membranes assessed as inhibition of orexin-A-induced intracellular calcium release after 120 mins | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804 | Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. |
| AID1237020 | Antagonist activity at orexin-1 receptor (unknown origin) | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 ISSN: 1464-3405 | Recent trends in orexin research--2010 to 2015. |
| AID1582240 | Displacement of [3H]4-(2,6-Difluoro-4-methoxybenzyl)-2-(5,6-dimethoxypyridin-3-yl)-2H-1,2,4-benzothiadiazin-3(4H)-one 1,1-dioxide from human wild-type OX2 receptor expressed in baculovirus infected Sf21 insect cell membranes measured after 90 mins by liqu | 2020 | Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4 ISSN: 1520-4804 | Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis. |
| AID1280003 | Clearance in iv dosed dog | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804 | Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. |
| AID1582239 | Displacement of [3H]4-(2,6-Difluoro-4-methoxybenzyl)-2-(5,6-dimethoxypyridin-3-yl)-2H-1,2,4-benzothiadiazin-3(4H)-one 1,1-dioxide from human wild-type OX1 receptor expressed in baculovirus infected Sf21 insect cell membranes measured after 90 mins by liqu | 2020 | Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4 ISSN: 1520-4804 | Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis. |
| AID1279997 | Plasma protein binding in rat | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804 | Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. |
| AID1190418 | Selectivity ratio of Ki for human OX1R to Ki for human OX2R | 2015 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3 ISSN: 1464-3405 | Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant. |
| AID1280009 | Ratio of drug level in CSF to plasma in rat | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804 | Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. |
| AID1279957 | Antagonist activity at human OX1R expressed in CHO cell membranes assessed as inhibition of orexin-A-induced intracellular calcium release after 120 mins | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804 | Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. |
| AID1190416 | Antagonist activity at human OX2R by FLIPR assay | 2015 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3 ISSN: 1464-3405 | Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant. |
| AID1279986 | Plasma protein binding in human | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804 | Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. |
| AID1280002 | Half life in iv dosed rat | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804 | Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. |
| AID1280004 | Half life in iv dosed dog | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804 | Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. |
| AID1279993 | Binding affinity to OX2R (unknown origin) | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804 | Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. |
| AID1280010 | Ratio of drug level in brain to plasma in rat | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804 | Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. |
| AID1279998 | Plasma protein binding in dog | 2016 | Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2 ISSN: 1520-4804 | Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 ISSN: 2472-5560 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346418 | Human OX2 receptor (Orexin receptors) | 2012 | Neuropharmacology, Feb, Volume: 62, Issue:2 ISSN: 1873-7064 | Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia. |
| AID1346381 | Human OX1 receptor (Orexin receptors) | 2012 | Neuropharmacology, Feb, Volume: 62, Issue:2 ISSN: 1873-7064 | Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 18 (85.71) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (19.05%) | 5.53% |
| Reviews | 6 (28.57%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (52.38%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| sb 408124 | organohalogen compound; quinolines | 2013 | 2020 | 7.5 | low | 0 | 0 | 0 | 0 | 2 | 0 | ||
| sb 334867-a | naphthyridine derivative | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | ||
| jnj 10397049 | 2013 | 2016 | 9.5 | medium | 0 | 0 | 0 | 0 | 2 | 0 | |||
| sb674042 | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |||
| tcs ox2 29 | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |||
| almorexant | isoquinolines | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 | ||
| suvorexant | 1,3-benzoxazoles; aromatic amide; diazepine; organochlorine compound; triazoles | central nervous system depressant; orexin receptor antagonist | 2013 | 2020 | 8.0 | low | 0 | 0 | 0 | 0 | 4 | 0 | |
| sb 649868 | 2013 | 2016 | 9.5 | medium | 0 | 0 | 0 | 0 | 2 | 0 | |||
| act-462206 | 2015 | 2020 | 7.0 | high | 0 | 0 | 0 | 0 | 3 | 0 | |||
| gsk 1059865 | 2013 | 2020 | 7.5 | high | 0 | 0 | 0 | 0 | 2 | 0 | |||
| act-335827 | 2013 | 2015 | 10.0 | high | 0 | 0 | 0 | 0 | 2 | 0 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| acetylene | alkyne; gas molecular entity; terminal acetylenic compound | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | ||
| piperidine | azacycloalkane; piperidines; saturated organic heteromonocyclic parent; secondary amine | base; catalyst; human metabolite; non-polar solvent; plant metabolite; protic solvent; reagent | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| thiazoles | 1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene | 2012 | 2014 | 11.0 | low | 0 | 0 | 0 | 0 | 3 | 0 | ||
| pyrimidine | diazine; pyrimidines | Daphnia magna metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| triazoles | 1,2,3-triazole | 2013 | 2018 | 9.0 | low | 0 | 0 | 0 | 0 | 4 | 0 | ||
| benzofurans | 2012 | 2014 | 11.0 | low | 0 | 0 | 0 | 0 | 3 | 0 | |||
| jnj 10397049 | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |||
| almorexant | isoquinolines | 2012 | 2014 | 11.0 | low | 0 | 0 | 0 | 0 | 3 | 0 | ||
| suvorexant | 1,3-benzoxazoles; aromatic amide; diazepine; organochlorine compound; triazoles | central nervous system depressant; orexin receptor antagonist | 2013 | 2018 | 9.0 | low | 0 | 0 | 0 | 0 | 3 | 0 | |
| sb 649868 | 2012 | 2014 | 11.0 | high | 0 | 0 | 0 | 0 | 3 | 0 | |||
| piperidines | 2012 | 2018 | 9.1 | high | 4 | 0 | 0 | 0 | 14 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal Migraine | 0 | 2015 | 2015 | 9.0 | low | 1 | 0 | 0 | 0 | 2 | 0 | |
| Anxiety | 0 | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Asymmetric Diabetic Proximal Motor Neuropathy | 0 | 2018 | 2018 | 6.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Chronic Insomnia | 0 | 2012 | 2016 | 9.7 | high | 1 | 0 | 0 | 0 | 6 | 0 | |
| Congenital Zika Syndrome | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Depression, Involutional | 0 | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Depressive Disorder, Major | 1 | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Diabetic Neuropathies | 1 | 2018 | 2018 | 6.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Disease Models, Animal | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Gelineau Syndrome | 0 | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Long Sleeper Syndrome | 0 | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Migraine Disorders | 0 | 2015 | 2015 | 9.0 | low | 1 | 0 | 0 | 0 | 2 | 0 | |
| Narcolepsy | 0 | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Sleep Initiation and Maintenance Disorders | 1 | 2012 | 2016 | 9.7 | high | 1 | 0 | 0 | 0 | 6 | 0 | |
| Sleep Wake Disorders | 0 | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Zika Virus Infection | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Article | Year |
|---|---|
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, , Volume: 96, Issue:5 | 2019 |
| Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia. Neuropharmacology, , Volume: 62, Issue:2 | 2012 |